RxDoctor Payments Data

Ran Lee, MD

Advanced Heart Failure and Transplant Cardiology · Cleveland, OHNPI 1518220136

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,200 of the $4,959 with a category attached, or 64.5%. 9 manufacturers reported payments, led by Getinge USA Sales, LLC at 47.1% of the total. Reporting peaked in 2023 at $4,131 and has fallen 86.7% since, to $551 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in OH, where the typical reported total is $4,421.

$4,959in general payments, 2019–2025

Across 20 payments — averaging $247.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Getinge USA Sales, LLC$2K
  • Maquet Cardiovascular L.L.C.$2K
  • Abiomed$410
  • Paragonix Technologies, Inc.$350
  • Datascope Corp.$96
  • Angiodynamics, Inc.$58
  • plus $107 from 3 others

What the payments were for

  • Consulting fees$3,20065%
  • Travel & lodging$64213%
  • Food & beverage$1,11823%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,959 in reported general payments places this provider in the 50th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.

See all advanced heart failure and transplant cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$157,147
Medicare patients
364
Services billed
1,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis47$1,057,195
EntrestoSacubitril/Valsartan250$353,576
JardianceEmpagliflozin217$278,495
FarxigaDapagliflozin Propanediol39$54,276
XareltoRivaroxaban30$43,290
EliquisApixaban31$37,334
Metoprolol Succinate166$2,372
Torsemide64$1,972
Spironolactone209$1,923
Amiodarone Hcl29$1,794
Carvedilol123$1,690
Atorvastatin Calcium84$1,281
Isosorbide Dinitrate11$1,134
Eplerenone11$752
Rosuvastatin Calcium37$589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$39$43,29030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.

Other advanced heart failure and transplant cardiology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →